| __timestamp | Apellis Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 49315000 |
| Thursday, January 1, 2015 | 6356782 | 75043000 |
| Friday, January 1, 2016 | 4303743 | 83749000 |
| Sunday, January 1, 2017 | 10463151 | 122682000 |
| Monday, January 1, 2018 | 22639184 | 207761000 |
| Tuesday, January 1, 2019 | 67046483 | 284812000 |
| Wednesday, January 1, 2020 | 139401000 | 317875000 |
| Friday, January 1, 2021 | 176771000 | 282660000 |
| Saturday, January 1, 2022 | 277163000 | 451421000 |
| Sunday, January 1, 2023 | 500815000 | 481871000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Sarepta Therapeutics, Inc. and Apellis Pharmaceuticals, Inc. have shown distinct strategies in handling these costs. From 2014 to 2023, Sarepta's SG&A expenses grew by approximately 880%, peaking at nearly $482 million in 2023. In contrast, Apellis saw a staggering increase of over 17,000%, reaching around $501 million in the same year.
While both companies have seen significant growth in their SG&A expenses, Apellis's rapid escalation suggests aggressive expansion or increased operational costs. Meanwhile, Sarepta's steadier rise may indicate a more controlled approach. Understanding these trends provides valuable insights into each company's strategic priorities and financial management. As the biotech industry continues to evolve, monitoring such financial metrics will be key to predicting future success.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights